We, therefore, sought to evaluate the impact of the concomitant use of APAP in patients with advanced NSCLC receiving PD-1/PD-L1-targeted agents, using real-world evidence from medical records available from our institutional database and registry of government agencies for monitoring high-cost drug prescriptions. Here, PDCD1 is linked to non-small cell lung carcinoma.